Science Letter
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Science Letter
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Heart Failure
Medication does not appear to improve symptoms or outcomes for patients with acute heart failure
November 20th, 2007
The medication tezosentan, which was thought could be beneficial for the treatment of acute heart failure, did not improve breathlessness or reduce the risk of fatal or nonfatal cardiovascular events, according to a study in the November 7 issue of JAMA. Patients with heart failure have higher plasma concentrations of the vasoconstrictor peptide endothelin-1 (a peptide that can cause narrowing of a blood vessel opening), which has been associated with worse clinical or health outcomes, according to background information in the article. Tezosentan is an intravenous short-acting endothelin receptor antagonist (a drug that neutralizes or counteracts the effects of another...
Source: Science Letter (2007-11-20)
|
